Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
114 hedge funds and large institutions have $1.43B invested in Audentes Therapeutics, Inc in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 20 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
39% more call options, than puts
Call options by funds: $2.85M | Put options by funds: $2.05M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
4% more capital invested
Capital invested by funds: $1.38B → $1.43B (+$53M)
7% less funds holding
Funds holding: 123 → 114 (-9)
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$42.1M |
| 2 |
NC
Nexthera Capital
New York
|
+$11.2M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$9.44M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$7.08M |
| 5 |
CC
Casdin Capital
New York
|
+$6.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$25.2M |
| 2 |
DM
Deerfield Management
New York
|
-$20.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 4 |
O
OrbiMed
New York
|
-$16.2M |
| 5 |
Millennium Management
New York
|
-$12.9M |
BOLD Hedge Fund Activity: Q3 2018 in Review
114 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2018, worth a combined $1.43B — up 3.8% from $1.38B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of BOLD and 11 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 44 added.
The largest buyer was PFM Health Sciences, adding an estimated $42.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $25.2M sold.
- 114 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2018, down from 123 in Q2 2018.
- Funds reported $1.43B of Audentes Therapeutics, Inc stock for Q3 2018, up 3.8% quarter-over-quarter.
- 11 funds opened new Audentes Therapeutics, Inc positions in Q3 2018 and 20 closed out, a net change of -9 holders.
- The largest Audentes Therapeutics, Inc buyer in Q3 2018 was PFM Health Sciences, an estimated $42.1M added.
- The largest Audentes Therapeutics, Inc seller in Q3 2018 was Perceptive Advisors, an estimated $25.2M sold.
Based on aggregated 13F filings for Q3 2018.